BioNTech Fangemeinde - Forschung ist die beste Medizin WKN: A2PSR2 ISIN: US09075V1026 Forum: Aktien User: Spoon

Bin bei Diba sehr zufrieden! Alles klappt reibungslos Ein paar Minuten nach Kauf oder Verkauf liegt die Abrechnung detailliert in meinen Postfach bei Diba.

Sind nur Sterne Ich such einen anderen Werde denke ich komplett zu diba gehen

*** bin top zufrieden

Hab da mal eine Frage ich möchte meinen Brocker wechseln könnte mir jemand einen guten empfählen

Und alles weil sie Verlust gemacht haben? Ist ja auch ein gutes Argument den Impfstoff nicht zum selbst kosten Preis zuverkaufen

Sorrento geht seit Tagen ab wie ein Zäpfchen. 🚀

https://www.finanzen.net/aktien/seres_therapeutics-aktie 🙈😒

BioNTech, Fosun Pharma launch COVID-19 vaccine trial in China https://seekingalpha.com/news/3600569

Die Tests in China haben begonnen 😃😃😃😃

https://finance.yahoo.com/quote/BNTX?p=BNTX

.

.

Alles von seeking alpha

The commercialization of all COVID-19 vaccines would therefore be worth $91.26bn based on 60% of the population per shot. The 2 initial shots will be worth twice that at $182.5bn. The 4 annual shots will be worth $365bn. Moving on to the BioNTech/Pfizer team and given its competitive advantages, it would be fair to estimate that it could capture up to 50% of the market, particularly in the 2020 to 2023 period. That would calculate a revenue stream of $91.26bn for the 1st two shots over 4 years and booster shots worth $182bn per annum after the 4 years. This is not a definitive calculation, it is an indicative calculation using current available information. The information and basis for calculation may change going forward or may substantially remain the same. We just do not know but these are very substantial potential revenue streams. The BioNTech/Pfizer team has not disclosed how they will share the potential revenue stream, but let’s use a 50/50 division for a calculation which will allow us to drill down to BioNTech. It then follows that BioNTech will build up to a revenue stream of $91.26bn by 2023 with substantial income generation already taking place in 2020. An enterprise value of 2 times revenue would indicate that BioNTech should grow to a market capitalization of around $182.5bn ignoring all its other potential products and the potential future income from the technology of having a proven mRNA delivery vehicle. BioNTech currently has 226 262 336 shares in issue, excluding a small rights offer in progress, for a market cap of around $20bn at its closing price on July 31, 2020, at $82.11. The share price will have to increase to $806 to reach a market cap of $182.5 but one would expect some dilution with rights offers along the way. It is reasonable to place a target price of $200-300 on BioNTech shares by the end of 2020 based on the information available. I believe that the information available also shows the BioNTech/Pfizer team to be in a commanding position to gain the largest market share from the development of a COVID-19 vaccine. October 2020 is a very near date for data and commercialization certainty. The governments of the USA, the UK and Japan seem to agree.

This is an important question for the number of vaccine doses to be commercialized. Moncef Slaoui asked, for how long will the vaccine afford efficacy? The reporter did not follow it up. BioNTech indicated that its vaccine achieved immune responses specific to the SARS-CoV-2 protein. Does that mean that its vaccine will last longer than 2 months to 3 months? In time we will have the data and the answer, but for now the biological answer is that immunity (judged by antibodies, which still needs to be proven) lasts 2 to 3 months. It follows that it is probable that people will have to receive booster shots every 2 to 3 months. That is why this question is controversial and why this aspect is underreported. The development path of the vaccine is already being questioned by anti-vaxxers and quarterly booster shots are certainly going to be controversial. We know from the clinical trial data above that the vaccine will most likely be delivered in two initial doses. Judging from the biological immune response data, it would be fair to expect a booster dose quarterly. I had mentioned above that BioNTech uses a custom made vehicle to deliver an inactive portion of the virus to the human body. The point is that the body must respond to the inactive portion of the COVID-19 causing virus and not to the vehicle. Using a naturally occurring virus as the vehicle can cause the body to respond to the "vehicle" rather than the COVID-19 causing virus, particularly if the body had previously encountered the "vehicle." This response to the vehicle may become an additional problem with multiple booster shots. Having a custom-built vehicle will be a significant advantage. Armed with the information above on the development progress, prospects for success, commercial positioning and competitive advantages, we can do initial calculations on the commercialization of a COVID-19 vaccine. That will assist us in estimating the commercial value for BioNTech and what a fair value would be for its shares. Who needs it? The whole world population of 7.8bn people. What is the indicative price? See the pre-order from the USA government, $1.95bn for 100 million doses. That is $19.5 per dose and each person will need 2 doses to start out. It is likely that each person would require quarterly booster shots. That means at least 4 shots per annum. Not everybody will get vaccinated but this is such an economic emergency that it is likely that vaccination will exceed 60%, so let’s work with 60% of the global population being vaccinated.

More information on the vaccines and how they work can be obtained from this excellent National Geographic article. On July 27, Pfizer and BioNTech launched a trial that combines phase two and three by enrolling a diverse population in areas with significant SARS-CoV-2 transmission. It will examine the vaccine’s effect in 30,000 people from 39 U.S. states and from Brazil, Argentina, and Germany.” The FDA approval benchmark for the COVID-19 vaccine is 50% efficacy and when the Operation Warp Speed chief adviser was asked by CNN Senior Medical Correspondent Elizabeth Cohen: “Some vaccines are 97% effective, others are 60%, where do you think we’re going to fall with the COVID vaccine?” he answered: It is very hard to predict, of cause, that’s why we are doing the trail. My personal opinion based on my experience and the biology of this virus, I think this vaccine is going to be highly efficacious. I wouldn't be surprised if it's in the 90% [range]." said Moncef Slaoui, chief adviser of Operation Warp Speed. "I think the question that’s open is, for how long will the vaccine afford efficacy." His final comment is very important, “for how long will the vaccine afford efficacy?” Research so far indicates that immunity fades within 2-3 months. CIDRAP, Centre for Infectious Disease and Policy at the University of Minnesota reports on a study in China that antibodies in COVID-19 patients fade quickly. “The study, which focused on 37 asymptomatic and 37 symptomatic patients, showed that more than 90% of both groups showed steep declines in levels of SARS-COV-2–specific immunoglobulin G (IgG) antibodies within 2 to 3 months after onset of infection, ...” Antibody levels dropped 70% Among the main findings was that IgG levels in 93% (28/30) of the asymptomatic group and 97% (30/31) of the symptomatic group declined greatly during the early convalescent phase (by 8 weeks after release from the hospital). Antibody levels dropped by 71.1% in asymptomatic patients and 76.2% in the symptomatic group.” I have mentioned that success means antibodies and T cell responses but now it seems that "success" is only going to last 2-3 months.